Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.

Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward? / Bianconi, Maristella; Faloppi, Luca; Del Prete, Michele; Giampieri, Riccardo; Bittoni, Alessandro; Lopez Beltran, Antonio; Scarpelli, Marina; Cheng, Liang; Scartozzi, Mario; Cascinu, Stefano; Montironi, Rodolfo. - In: ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY. - ISSN 0884-6812. - STAMPA. - 37:1(2015), pp. 3-13.

Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward?

FALOPPI, LUCA;GIAMPIERI, RICCARDO;BITTONI, ALESSANDRO;SCARPELLI, Marina;MONTIRONI, RODOLFO
2015-01-01

Abstract

Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.
2015
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/233598
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact